• LAST PRICE
    1.0300
  • TODAY'S CHANGE (%)
    Trending Down-0.0400 (-3.7383%)
  • Bid / Lots
    1.0300/ 1
  • Ask / Lots
    1.0500/ 5
  • Open / Previous Close
    1.0700 / 1.0700
  • Day Range
    Low 1.0200
    High 1.0700
  • 52 Week Range
    Low 0.9801
    High 7.7500
  • Volume
    6,172
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.07
TimeVolumeBACK
09:32 ET1161.07
10:13 ET2501.06
10:51 ET4801.06
10:54 ET36941.0201
11:09 ET1001.035
11:43 ET1001.04
12:08 ET1001.03
12:14 ET6861.03
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBACK
IMAC Holdings Inc
1.9M
-0.2x
---
United StatesPTSH
PTS Inc
1.9M
---
---
United StatesMDRM
Modern Mobility Aids Inc
2.7M
-0.2x
---
United StatesMITI
Mitesco Inc
2.8M
-0.9x
---
United StatesCYBQY
Cyberdyne Inc
169.7M
-33.6x
---
United StatesALBT
Avalon Globocare Corp
2.7M
-0.1x
---
As of 2024-11-26

Company Information

IMAC Holdings, Inc. is a clinical research and commercialization company. The Company is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. The Company is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease. The Company is also engaged in providing the precision medicine business. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.

Contact Information

Headquarters
3401 MALLORY LANE, SUITE 100FRANKLIN, TN, United States 37067
Phone
---
Fax
302-655-5049

Executives

Chief Executive Officer
Faith Zaslavsky
Chief Financial Officer
Sheri Gardzina
Director
Peter Beitsch
Director
Matthew Schwartz
Independent Director
Maurice Evans

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.9M
Revenue (TTM)
$0.00
Shares Outstanding
1.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.29
EPS
$-5.04
Book Value
$-0.66
P/E Ratio
-0.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.